International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
Potential clinical actionability of metagenomic next-generation sequencing for antimicrobial stewardship for urinary tract infections: a retrospective, single-centre, BI-Biotia UTI cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wangprapa Panupong, Nagy-Szakal Dorottya, Wells Heather L, Fidler Gabor, Techasathit Wichai, Couto-Rodriguez Mara, Danko David C, Mason Christopher E, O'Hara Niamh B, Sangtian Montinee, Viangteeravat Teeradache, Sriswasdi Sira
Аннотация
OBJECTIVES: Culture and antimicrobial susceptibility testing (AST) take 48-72 hours, leaving empirical therapy for urinary tract infections (UTIs) without resistance data. Metagenomic next-generation sequencing (mNGS) reports resistance within hours, but its potential clinical actionability for prescribing is underexplored.
METHODS: In a retrospective single-centre cohort (Bangkok tertiary hospital, 2018-2020), BIOTIA-DX results were compared with culture and AST in 251 culture-paired samples. Potential clinical actionability was assessed for 54 same-day empirical prescriptions and a post hoc ablation estimated what a rule-based policy would have prescribed under different information from mNGS.
RESULTS: Twenty-two of 54 prescriptions (40·7%, 95% CI 28·7-54·0) were potentially actionable: treatment failure prevention 9 (16·7%) and de-escalation 13 (24·1%). Excluding blaEC and blaACT raised cephalosporin specificity from 25·6% to 78·9% with a small tradeoff in sensitivity. NPVs were at least 89·7% for carbapenems, cephalosporins, trimethoprim/sulfamethoxazole, aminoglycosides and the fluoroquinolone classifier reached 100·0% PPV in Escherichia coli. Our refined resistance classification rules achieved a good tradeoff between the risk of ineffective antibiotics and the use of broad-spectrum carbapenem, compared with observed prescribing.
CONCLUSIONS: In a high-resistance setting, a same-day mNGS report was potentially actionable for two in five empirical prescriptions, mainly through resistance calling. However, the findings rest on a small number of cases.
METHODS: In a retrospective single-centre cohort (Bangkok tertiary hospital, 2018-2020), BIOTIA-DX results were compared with culture and AST in 251 culture-paired samples. Potential clinical actionability was assessed for 54 same-day empirical prescriptions and a post hoc ablation estimated what a rule-based policy would have prescribed under different information from mNGS.
RESULTS: Twenty-two of 54 prescriptions (40·7%, 95% CI 28·7-54·0) were potentially actionable: treatment failure prevention 9 (16·7%) and de-escalation 13 (24·1%). Excluding blaEC and blaACT raised cephalosporin specificity from 25·6% to 78·9% with a small tradeoff in sensitivity. NPVs were at least 89·7% for carbapenems, cephalosporins, trimethoprim/sulfamethoxazole, aminoglycosides and the fluoroquinolone classifier reached 100·0% PPV in Escherichia coli. Our refined resistance classification rules achieved a good tradeoff between the risk of ineffective antibiotics and the use of broad-spectrum carbapenem, compared with observed prescribing.
CONCLUSIONS: In a high-resistance setting, a same-day mNGS report was potentially actionable for two in five empirical prescriptions, mainly through resistance calling. However, the findings rest on a small number of cases.